124 related articles for article (PubMed ID: 17262997)
1. Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years.
Lopatinskaya L; Zwemmer J; Uitdehaag B; Lucas K; Polman C; Nagelkerken L
Mult Scler; 2006 Dec; 12(6):704-9. PubMed ID: 17262997
[TBL] [Abstract][Full Text] [Related]
2. The development of clinical activity in relapsing-remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood.
Lopatinskaya L; van Boxel-Dezaire AH; Barkhof F; Polman CH; Lucas CJ; Nagelkerken L
J Neuroimmunol; 2003 May; 138(1-2):123-31. PubMed ID: 12742662
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of apoptosis-related genes: Fas (CD94), FasL (CD178) and TRAIL polymorphisms in Iranian multiple sclerosis patients.
Mohammadzadeh A; Pourfathollah AA; Sahraian MA; Behmanesh M; Daneshmandi S; Moeinfar Z; Heidari M
J Neurol Sci; 2012 Jan; 312(1-2):166-9. PubMed ID: 21864851
[TBL] [Abstract][Full Text] [Related]
4. Differential susceptibility to apoptosis of CD4+T cells expressing CCR5 and CXCR3 in patients with MS.
Julià E; Edo MC; Horga A; Montalban X; Comabella M
Clin Immunol; 2009 Dec; 133(3):364-74. PubMed ID: 19740704
[TBL] [Abstract][Full Text] [Related]
5. Anti-HHV-6 IgG titer significantly predicts subsequent relapse risk in multiple sclerosis.
Simpson S; Taylor B; Dwyer DE; Taylor J; Blizzard L; Ponsonby AL; Pittas F; Dwyer T; van der Mei I
Mult Scler; 2012 Jun; 18(6):799-806. PubMed ID: 22084489
[TBL] [Abstract][Full Text] [Related]
6. [Clinical evaluation of follow-up and disease course].
Roullet E
Rev Neurol (Paris); 2001 Sep; 157(8-9 Pt 2):1121-3. PubMed ID: 11787343
[TBL] [Abstract][Full Text] [Related]
7. Increase in CCR5 Delta32/Delta32 genotype in multiple sclerosis.
Pulkkinen K; Luomala M; Kuusisto H; Lehtimäki T; Saarela M; Jalonen TO; Elovaara I
Acta Neurol Scand; 2004 May; 109(5):342-7. PubMed ID: 15080861
[TBL] [Abstract][Full Text] [Related]
8. Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis.
Stauch C; Reiber H; Rauchenzauner M; Strasak A; Pohl D; Hanefeld F; Gärtner J; Rostásy KM
Mult Scler; 2011 Mar; 17(3):327-34. PubMed ID: 21123302
[TBL] [Abstract][Full Text] [Related]
9. Correlation between disease severity and in vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein in patients with multiple sclerosis.
Rolland A; Jouvin-Marche E; Saresella M; Ferrante P; Cavaretta R; Créange A; Marche P; Perron H
J Neuroimmunol; 2005 Mar; 160(1-2):195-203. PubMed ID: 15710473
[TBL] [Abstract][Full Text] [Related]
10. Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.
Killestein J; Den Drijver BF; Van der Graaff WL; Uitdehaag BM; Polman CH; Van Lier RA
Mult Scler; 2001 Jun; 7(3):145-50. PubMed ID: 11475436
[TBL] [Abstract][Full Text] [Related]
11. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
Vollmer TL; Wynn DR; Alam MS; Valdes J
Mult Scler; 2011 Feb; 17(2):181-91. PubMed ID: 21135022
[TBL] [Abstract][Full Text] [Related]
12. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
[TBL] [Abstract][Full Text] [Related]
13. Antinuclear and antiphospholipid antibodies in patients with multiple sclerosis.
Szmyrka-Kaczmarek M; Pokryszko-Dragan A; Pawlik B; Gruszka E; Korman L; Podemski R; Wiland P; Szechinski J
Lupus; 2012 Apr; 21(4):412-20. PubMed ID: 22074845
[TBL] [Abstract][Full Text] [Related]
14. Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis.
Amor S; van der Star BJ; Bosca I; Raffel J; Gnanapavan S; Watchorn J; Kuhle J; Giovannoni G; Baker D; Malaspina A; Puentes F
Mult Scler; 2014 Sep; 20(10):1355-62. PubMed ID: 24515731
[TBL] [Abstract][Full Text] [Related]
15. Primary progressive versus relapsing-onset multiple sclerosis: presence and prognostic value of cerebrospinal fluid oligoclonal IgM.
Sola P; Mandrioli J; Simone AM; Ferraro D; Bedin R; Annecca R; Venneri MG; Nichelli PF; Merelli E
Mult Scler; 2011 Mar; 17(3):303-11. PubMed ID: 21078694
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course.
Khademi M; Kockum I; Andersson ML; Iacobaeus E; Brundin L; Sellebjerg F; Hillert J; Piehl F; Olsson T
Mult Scler; 2011 Mar; 17(3):335-43. PubMed ID: 21135023
[TBL] [Abstract][Full Text] [Related]
17. T2 lesions and rate of progression of disability in multiple sclerosis.
Mostert JP; Koch MW; Steen C; Heersema DJ; De Groot JC; De Keyser J
Eur J Neurol; 2010 Dec; 17(12):1471-5. PubMed ID: 20500805
[TBL] [Abstract][Full Text] [Related]
18. Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression.
Teunissen CE; Sombekke M; van Winsen L; Killestein J; Barkhof F; Polman CH; Dijkstra CD; Blankenstein MA; Pratico D
Mult Scler; 2012 Aug; 18(8):1092-8. PubMed ID: 22695538
[TBL] [Abstract][Full Text] [Related]
19. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis.
Ge Y; Grossman RI; Udupa JK; Wei L; Mannon LJ; Polansky M; Kolson DL
Radiology; 2000 Mar; 214(3):665-70. PubMed ID: 10715027
[TBL] [Abstract][Full Text] [Related]
20. Analysis of immunoregulatory T-helper cell subsets in patients with multiple sclerosis: relapsing-progressive course correlates with enhanced T H1, relapsing-remitting course with enhanced T H0 reactivity.
Barth H; Klein K; Börtlein A; Guseo A; Berg PA; Wiethölter H; Klein R
J Neuroimmunol; 2002 Dec; 133(1-2):175-83. PubMed ID: 12446020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
